We are here to serve you

For a full list of the medications that we provide, please visit the Medications page click HERE

  • 21-day Detox (Short Term): The patient will be stabilized and tapered off their prescribed medication within a 21-day period. Traditionally this program has been most effective when utilizing methadone as the medication provided.
  • 180-day Detox (Long Term): The patient will be stabilized on their prescribed medication and slowly tapered off over a 6 month period. The patient may complete this program prior to 180 days when clinically appropriate.
  • Maintenance: The patient will be stabilized on their selected/appropriate medication and the dose will be maintained throughout the course of treatment. The length of treatment will be determined by the physician and patient, as this program offers ongoing treatment without a specific end date. Pregnant patients are included under this program.

What we offer

  • Counseling
  • Case Management
  • Crisis Intervention
  • Drug Education
  • Patient Advocacy
  • Urine Tests

What Our Treatment Protocol Consists Of

  • Screening
  • Intake
  • Orientation
  • Assessment
  • Treatment Planning
  • Counseling
  • Case Management
  • Crisis Intervention
  • Patient/Client Education
  • Referral
  • Report & Record Keeping
  • Consultation with other professionals in regard to client treatment
  • use disorder counselors / Case Managers
  • Licensed nurses (RN & LVN)

Initially, the patient must visit the clinic regularly and receive his/her medication, yet over time the successful patient earns privileges. These can include fewer clinic visits and eligibility for take home medications as allowed by state regulation.

SOAP MAT focuses on breaking the destructive cycle of opioid use disorder and dependency, understands the difficulties of the social stigma associated with experiencing substance use disorders and believes an independent and constructive lifestyle is attainable. SOAP staff members believe that all patients should be treated with dignity and respect and are committed to delivering quality healthcare services in a compassionate and supportive environment.

Medications developed to treat opioid use disorder work through the same receptors as opioids, but are safer and less likely to produce the harmful behaviors that characterize substance use disorders. Physicians prescribe a particular medication based on a patient’s specific medical needs to help reduce withdrawal symptoms and cravings. Methadone and buprenorphine are medications used to treat opioid dependence and misuse. People may safely take medications used in MAT for months, years, several years, or even a lifetime.

Taking medication for opioid use disorder is like taking medication to control heart disease or diabetes. It is not the same as substituting one drug for another. The prescribed medication operates to normalize brain chemistry, block the euphoric effects of opioids, relieve physiological cravings, and normalize body functions without the negative effects of the abused drug. If controlled and used properly, the medication does not create a new misuse but helps people manage substance use disorder symptoms so that the benefits of recovery can be maintained. In turn, patients are better able to focus on the lifestyle changes that lead back to healthy living.

Jail Dosing

Whenever possible, SOAP MAT counselors cooperate with local jails to encourage continuity of treatment for incarcerated maintenance treatment patients. If an agreement is in place with the jail, for an additional fee a detoxification regimen can be implemented with the patient upon notification of the patient’s incarceration.

Due to the numerous restrictions that are in place at the detention facilities, we cannot guarantee we will gain access to medicate patients while they are incarcerated, and as noted above, there is an additional fee for this service.

 

The Treatment Solution

Overall, treatment of substance use disorders is as successful as treatment of other chronic diseases, such as diabetes, hypertension, and asthma.

Methadone is one of the longest-established, most thoroughly evaluated forms of drug treatment. The science is overwhelming in its findings about methadone treatment’s effectiveness. For example, a Drug Abuse Treatment Outcomes Study by the National Institute on Drug Abuse (NIDA) found that methadone treatment reduced participants’ heroin use by 70%, reduced criminal activity by 57%, and increased full-time employment by 24%.1 It also reduces deaths—the median death rate of opiate-dependent individuals in treatment is 30 percent of the rate of those not in treatment.2

Suboxone, a medication combining buprenorphine and naloxone, has demonstrated significant efficacy in treating opioid use disorder (OUD), as supported by historical evidence. Numerous studies have consistently shown its effectiveness in reducing opioid cravings, preventing withdrawal symptoms, and promoting long-term recovery. A randomized controlled trial conducted by Ling et al. (2005) involving 326 participants with OUD found that Suboxone was superior to both placebo and buprenorphine alone in reducing illicit opioid use. The study revealed that Suboxone treatment resulted in significantly higher rates of treatment retention, lower rates of opioid-positive urine samples, and greater reductions in self-reported illicit opioid use.3

Moreover, additional evidence supporting the efficacy of Suboxone comes from a systematic review and meta-analysis by Mattick et al. (2014). The review analyzed data from 31 studies involving over 5,400 participants with OUD. The findings demonstrated that Suboxone was consistently associated with decreased illicit opioid use, improved treatment retention, and reduced mortality rates compared to placebo and non-pharmacological interventions. Furthermore, the review highlighted the importance of Suboxone in reducing the risk of HIV infection and criminal activity among individuals with OUD. These historical studies and reviews provide robust evidence of Suboxone’s efficacy as a treatment option for opioid use disorder.4

References

  1. McCaffrey, Barry, Statement of ONDCP Director Barry McCaffrey on Mayor Giuliani’s Recent Comments on Methadone Therapy, (Press Release) (Washington, DC: ONDCP), July 24, 1998.
  2. CDC publication on IDU HIV Prevention. Methadone Maintenance Treatment, February 2002.
  3. Ling, W., Amass, L., Shoptaw, S., Annon, J. J., Hillhouse, M., Babcock, D., … & Bickel, W. K. (2005). A multicenter randomized trial of buprenorphine–naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction, 100(8), 1090-1100.
  4. Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, (2), CD002207.

Additional Sources

  • SAMHSA National Clearinghouse for Drug and Alcohol Information
  • Office of National Drug Control Policy Drug Facts

CONTACT US

  • This field is for validation purposes and should be left unchanged.
Please enable JavaScript in your browser to complete this form.
Name